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Background: Mycophenolic acid (MPA) is an important immunosuppressive drug (ISD)
prescribed to prevent graft rejection in the organ transplanted patients, however, its use is
also associated with adverse side effects like sporadic gastrointestinal (GI) disturbances.
Recently, we reported the MPA induced tight junctions (TJs) deregulation which involves
MLCK/MLC-2 pathway. Here, we investigated the global histone acetylation as well as
gene-specific chromatin signature of several genes associated with TJs regulation in
Caco-2 cells after MPA treatment.
Results : The epigenetic analysis shows that MPA treatment increases the global
histone acetylation levels as well as the enrichment for transcriptional active histone
modification mark (H3K4me3) at promoter regions of p38MAPK, ATF-2, MLCK, and
MLC-2. In contrast, the promoter region of occludin was enriched for transcriptional
repressive histone modification mark (H3K27me3) after MPA treatment. In line with the
chromatin status, MPA treatment increased the expression of p38MAPK, ATF-2, MLCK,
and MLC-2 both at transcriptional and translational level, while occludin expression
was negatively influenced. Interestingly, the MPA induced gene expression changes and
functional properties of Caco-2 cells could be blocked by the inhibition of p38MAPK
using a chemical inhibitor (SB203580).
Conclusions : Collectively, our results highlight that MPA disrupts the structure of TJs
via p38MAPK-dependent activation of MLCK/MLC-2 pathway that results in decreased
integrity of Caco-2 monolayer. These results led us to suggest that p38MAPK-mediated
lose integrity of epithelial monolayer could be the possible cause of GI disturbance
(barrier dysfunction) in the intestine, leading to leaky style diarrhea observed in the
organ-transplanted patients treated with MPA.
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INTRODUCTION
Mycophenolate mofetil (MMF) and enteric-coated
mycophenolate-sodium (EC-MPS) are two commercially
available formulations of immunosuppressive regimens that
contain active agent mycophenolic acid (MPA; Bunnapradist
et al., 2014; Xu et al., 2014). MPA inhibits the activity of inosine
monophosphate dehydrogenase (IMPDH), a vital enzyme in
the de novo synthesis of guanine nucleotide, thus preventing
the synthesis of DNA and thereby inhibits growth and division
of rapidly growing cells such as lymphocytes of the immune
system (Watts, 1983). This property makes MPA as an effective
immunosuppressive regime to suppress the immune system in
order to prevent graft rejection in organ transplanted patients.
Though MPA is vital to suppress the immune system to prevent
graft rejection, its use is linked to the gastrointestinal (GI)
disturbances in the transplanted patients (for details, see review
articles Helderman and Goral, 2002; Malinowski et al., 2011).
Several studies have shown that defect in the intestinal barrier
function due to MMF or EC-MPS treatment results in increased
permeability of intestinal mucosa (epithelial monolayer) for the
solutes (Bunnapradist et al., 2014), develop leak-flux diarrhea
in the rat model (Xu et al., 2014), and in renal and kidney
transplanted patients (Watts, 1983; Helderman and Goral, 2002).
Gastrointestinal disturbances in inflammatory bowel diseases
(IBD) like Crohn’s disease and ulcerative colitis, and in
graft vs. host disease are mainly characterized by epithelial
monolayer barrier defects which contribute to enhanced
intestinal permeability (Clayburgh et al., 2004) and subsequent
translocation of infectious agents and/or endotoxin from gut
(Deitch, 2002; Magnotti and Deitch, 2005). Epithelial cells are
connected with each other by four different types of junctions
called desmosomes, gap-, adheren-, and, tight- junctions (TJs;
Costa et al., 2013; Hong et al., 2013; Siljamäki et al., 2014). TJs
are complex structure of∼35 different proteins including integral
membrane proteins (claudins, occludin, junctional adhesion
molecules “JAMs”) and peripheral membrane proteins [Zonula
Occludens (ZO) such as ZO-1, ZO-2, and ZO-3; Tsukita et al.,
2001; Schneeberger and Lynch, 2004]. TJs assist to seal the
paracellular space between the adjacent cells, and is particularly
involved in regulating barrier and fence functions (Shen et al.,
2011). In “barrier function,” TJs regulate the passage of ions,
water, and various molecules through paracellular pathways.
Thus, aberrant barrier function can cause edema, jaundice,
diarrhea, and blood-borne metastasis, however, the cell polarity
is maintained by forming a fence to prevent intermixing of
molecules between apical and lateral membrane. It is interesting
to note that the altered fence function is involved in cancer
progression in terms of loss of cell polarity (Sawada, 2013).
In GI tract, TJs opening is considered as a key limiting
factor ofmucosal paracellularmovement of nutrients and solutes.
Growing evidences have indicated that TJs opening is modulated
Abbreviations: MPA, mycophenolic acid; p38MAPK, p38 mitogen activated
protein kinase; ATF-2, activating transcription factor-2; MLCK, myosin light
chain kinase; MLC-2, myosin light chain-2; TJs, tight junctions; ZO-1, Zonula
Occludins; IL-1β, Interleukin-1 beta; TNF-α, Tumor necrosis factor-alpha; INF-γ,
Interferon-γ.
by the phosphorylation of myosin light chain 2 (MLC2), which
principally depends upon the activation of MLC kinase (MLCK).
TheMLCK itself is however triggered by different types of stimuli
such as IFN-gamma, TNF-alpha, and LIGHT (Lymphotoxin-
like inducible protein that competes with glycoprotein D for
herpes virus entry on T cells). This stimulation results in
contraction of cytoplasmic actin filaments and redistribution of
TJs anchoring protein, ZO-1 and structural protein, occludin
in IBD (Crohn’s disease, ulcerative disease), leaky flux diarrhea,
and cholera (watery diarrhea; Zolotarevsky et al., 2002; Utech
et al., 2005; Schwarz et al., 2007; Marchiando et al., 2010; Qasim
et al., 2014). Recently, it has been shown that proinflammatory
cytokine (IL-1β) induces TJs permeability in both in vitro and
in vivo models through p38MAPK/ATF-2-dependent regulation
of MLCK activity (Al-Sadi et al., 2013). p38MAPK is activated
by various cellular stress agents (i.e., UV irradiation, heat shock,
osmotic stress, lipopolysaccharide, cytokines; Mittelstadt et al.,
2005; Keren et al., 2006) and is known to play a vital role
in apoptosis, cytokines production, transcriptional regulation,
and cytoskeletal reorganization (Kelkar et al., 2005; Lee and
Dominguez, 2005; Baan et al., 2006). Previously, we reported that
MPA alters TJs assembly in Caco-2monolayer, similar to GI tract,
via MLCK/MLC-2 pathway (Qasim et al., 2014).
The aim of the present study was to investigate whether MPA
treatment leads to increased TJs permeability via p38MAPK
dependent MLCK/MLC-2 pathway in MPA-treated Caco-2 cells
monolayer.
MATERIALS AND METHODS
Experimental Design
We used Caco-2 cells as a model cell line to investigate
the MPA-mediated TJs modulation via p38MAPK dependent
MLCK/MLC-2 pathway. Toward this, we established three
groups: (1). MPA-treated group, (2). SB+MPA-treated group,
and (3). DMSO (control)-treated group of differentiated and
polarized Caco-2 cells monolayers. Each group was treated
with MPA or SB+MPA or DMSO for 72 h. Different molecular
analyses (epigenetic, mRNA expression, protein expression,
and phosphorylation status) and functional analyses (TEER
and FITC-Dextran dye flux) were performed to explore
the role of p38MAPK-dependent MLCK/MLC-2 pathway in
maintaining epithelial monolayer integrity following MPA
treatment.
Chemicals/Reagents
Cell culture media Dulbecco’s Modified Eagle’s medium
(DMEM), fetal calf serum (FCS), phosphate buffer saline
(PBS), penicillin and streptomycin were purchased from PAA
Laboratories, Pasching, Austria. Fluorescein isothiocyanate-
conjugated dextran (FITC-dextran), 4 kDa (FD4), Trypsin,
MPA, and DMSO were purchased from Sigma-Aldrich,
Steiheim, Germany. Protease and phosphatase inhibitor
cocktails were purchased from Roche, Mannheim, Germany.
Bromophenol blue was obtained from Carl Roth, Karlsruhe,
Germany. Sodium dodecyl sulfate (SDS) was obtained
from Serva, Heidelberg, Germany. Glycerin, potassium
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ferricynaide, and sodium thiosulfate were purchased from
Merck, Darmstadt, Germany. Formic acid was purchased
from BASF, Ludwigshafen, Germany. Magnesium chloride
(MgCl2), M-MLV RT enzyme, and 5X PCR buffer were from
Invitrogen, Karlsruhe, Germany. Deoxynucleotide triphosphates
(dNTPs) were from Roche, Mannheim, Germany and PCR
primers were synthesized by Eurofins, Ebersberg, Germany.
Ribonuclease (RNAase) inhibitor was obtained from Promega,
Mannheim, Germany. The cell lysis buffer (10X) was obtained
from Cell Signaling Technology, Danvers, MA, USA. All
other chemicals used in this work were from the highest
available purity from commercial sources unless otherwise
stated.
Primer Design
Promoter sequences were retrieved for each gene using
Transcriptional Regulatory Element Database (TRED). Primer3
(v. 0.4.0) was used to design primers against promoter region and
their specificity was checked by Human BLAT Search.
Cell Culture
All experiments were performed with human colon carcinoma
(Caco-2) cells (Passages No. 15-25). Caco-2 cells were purchased
from DSMZ (German collection of microorganisms and cell
culture, Braunschweig, Germany) and grown in DMEMmedium
supplemented with 10% FBS, 1% Penicillin/Streptomycin, 1%
non-essential amino acids. Confluent monolayers were obtained
within 3–5 days after cell seeding (2 × 105 cells/cm2) and grown
further for 13 days (d) post-confluency. Medium was changed
every other day after formation of confluent monolayer. Three
groups were established i.e., MPA-treated, SB203580 (SB)+MPA-
treated, and DMSO treated (control group). Cells were washed
with PBS prior to the 72 h exposure with either MPA (10µM)
or DMSO. In case of SB (10µM) treatment, cells were incubated
with SB 1 h prior to the addition of MPA.
Caco-2 Monolayer Integrity Assays
Determination of Trans-Epithelial Electrical
Resistance (TEER)
The intactness of paracellular pathways that control small
molecules movement across Caco-2 monolayer was examined by
TEER as previously described (Feldman et al., 2007; Qasim et al.,
2014). Briefly, Caco-2 cells were seeded on polyester transwell
inserts (6.5mm diameter, 0.33 cm2 growth surface area, 0.4µm
pore size; Corning Costar corporation, USA) at a density of
2 × 105 cells/well. Stable TEER of confluent monolayer was
achieved at days 13–15 after seeding. Caco-2 plated filter having
constant TEER (≥400 .cm2) were included in experiments.
Post-confluence monolayers having stable TEER were treated
withMPA or SB plusMPA orDMSO (control) for 72 h. TEERwas
measured at 0, 12, 24, 48, and 72 h time period using an epithelial
voltammeter (EVOM2, World Precision Instruments) with a
STX2 electrode (World Precision Instruments, FL, USA). The
TEER-values were normalized against background resistance of
a blank insert that contained only medium. TEER was measured
as ohms × cm2 (.cm2) using the following formula: Resistance
(TEER) = [RC – RE] × A, where RC is resistance of the cells
(); RE is resistance of the blank (); A is surface area of
the membrane insert (cm2). The results were expressed as the
change in TEER with respect to time-matched controls [1TEER
(.cm2)]. TEER-values were calculated in three independent
biological replicates each performed in duplicates.
FITC-Dextran Assay (FD4)
After 72 h of incubation with MPA or SB plus MPA or
DMSO, permeability of Caco-2 monolayers was assessed
using a previously reported dye fluxes method (Schlegel
et al., 2011; Qasim et al., 2014). Briefly, Caco-2 cells were
grown into monolayers and treated as described above.
FollowingMPA treatment, monolayers were rinsed carefully with
Hank’s balanced salt solution (HBSS). To measure paracellular
permeability (apical to basolateral fluxes), HBSS containing
1mg/mL FD4 solution was added to the apical side for 2 h.
Permeability marker flux was assessed by taking 100µL from
the basolateral chamber after 0, 20, 40, 60, 80, 100, and 120min.
Fluorescent signal was measured using a Lambda fluoro 320
fluorescence plate reader (MWG Biotech, Ebersberg, Germany)
using 492 nm excitation and 520 nm emission filters. Standard
curve, generated by serial dilution of FD4, was used to determine
the FD4 flux concentrations across the monolayer. The flux
concentration, which represents the permeability of monolayer,
in the basolateral chamber was calculated by the following
formula “Papp = [(1CA/1t) VA]/ACL.” Where Papp is the
apparent permeability (cm/s), 1CA is the change of FD4
concentration, A is the surface area of the membrane (cm2), 1t
is the change of time, VA is the volume of the abluminal medium,
and CL is the initial concentration in the luminal chamber. FD4-
values were calculated in three consecutive experiments, each
performed in duplicates.
RNA Expression Analysis
Cells were grown for 13 d post-confluence and treated for 72 h
in six-well plates as described above. Trizol (Trizol reagent;
Invitrogen, USA) was used to extract total cellular RNAs from
Caco-2 cell monolayers (MPA-treated or SB plus MPA-treated
or DMSO-treated) according to the manufacturer’s instructions.
Briefly, Caco-2 monolayers were rinsed with ice-cold PBS and
harvested by scraping with a rubber policeman into Trizol
reagent, homogenized by inverting the tube twice, and RNA
was extracted using chloroform/isopropanol precipitation. The
precipitated RNA was air dried, dissolved in sterile water and
stored at –80◦C until analysis. RNA was quantified using a
NanoDrop 2000C (PeqLab, Thermo Scientific).
Reverse transcription reaction was performed using 1µg
of total RNA in a 30µL reaction mixture containing 1X
RT-PCR buffer [10mmol/L Tris–HCl (pH 8.3), 15mmol/L
KCl, 0.6mmol/L MgCl 2], 0.5µmol/L of each dNTP, 1 U/µL
RNase inhibitor and 13.3 U/µL M-MLV RT enzyme. The
RT reactions were performed in a thermocycler (Biometra,
Goettingen, Germany) at 65◦C for 5min, 37◦C for 52min, and
then inactivated by heating at 70◦C for 15min. cDNA was stored
at −80◦C until use. Online Primer 3 software was used to design
primers for the amplification of target genes by real time PCR
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(Rozen and Skaletsky, 2000; For primers used in this study see
Table 1).
Light Cycler instrument (Roche, Manheim, Germany) was
used to amplify cDNA in a 20µL reaction mixture containing
1µL of cDNA solution, 2µL of 10X PCR buffer (Invitrogen,
Darmstadt, Germany), 2µL SYBR green, 1µL DMSO, 0.25µL
of each primer, 2.0mmol/L MgCl2, 0.2mmol/L of each dNTP,
and 0.15 U/µL PAN Script DNA polymerase (PAN Biotech,
Aidenbach, Germany). The following conditions were set to
amplify cDNA; [(denaturation: 95◦C for 5min, one cycle);
(40 cycles, denaturation: 95◦C for 30 s, (annealing: p38MAPK
(56◦C), ATF-2 (57◦C), MLCK (56◦C), MLC-2 (57◦C), occludin
(57◦C), ZO-1 (57◦C), and GAPDH (60◦C) for 30 s), extension
(72◦C) for 30 s)].
PCR data was normalized using internal control gene
(GAPDH) and comparative Ct method (2−11Ct; Schmittgen and
Livak, 2008) was used to calculate the alteration of relative mRNA
expression as a fold change between MPA treated and control
cells. Amplified PCR product specificity was further confirmed
by running on 1.5% agarose gel electrophoresis. Three separate
experiments were performed with each one in triplicates.
Dot Blot
Dot blot assay was performed as described previously (Bölin
et al., 1995) with little modification. Briefly, Caco-2 cells were
cultured into differentiated and polarizedmonolayers and treated
with the therapeutic concentration of MPA or DMSO for
72 h. Total cell lysate was prepared by 1X lysis buffer (Cell
Signaling) at 0, 1, 12, 24, 48, 72 h. Proteins were quantified
by Bio-Rad protein assay kit according to the manufacturer’s
guidelines. One centimeter square (cm2) grid was drawn by
pencil on nitrocellulose membrane. Two microliters (protein
concentration 10µg/µl) of each sample was slowly spotted into
the center of grid using narrow-mouth pipette tips. Sample
spotted membranes were dried at RT. Non-specific binding sites
were blocked by soaking sample spotted membrane in 5% BSA in
TBST for 1 h at RT on a plate shaker at low speed. Eachmembrane
was incubated with primary antibody (05µg/ml rabbit anti-
H3K9ac—Abcam or 1:20,000 rabbit anti-H4K8ac—Diagenode)
dissolved in 5% BSA/TBST for 2 h at RT on a plate shaker at
low speed. Following incubation with primary antibodies, each
membrane was washed three times for 5min and then incubated
with secondary antibodies conjugated with HRP for 1 h at RT
on a plate shaker at low speed. Then the membrane was washed
three times and incubated with ECL reagents for 2min, covered
with saran-wrap and exposed to X-ray film in the dark room for
different time, and proceeded for autoradiography using Konica
SRX-101A (Konica Minolta).
Western Blot
Caco-2 cells were cultured into differentiated and polarized
monolayers and treated as described above and were rinsed
and collected with ice-cold PBS. Cells were lysed with lysis
buffer-CS (50mM Tris/HCl, pH 7.4, 1.0% Triton X-100, 5mM
EGTA, 10mM sodium fluoride, 2µg/mL leupeptin, 10µg/mL
aprotinin, 10µg/mL bestatin, 10µg/mL pepstatin A, 1mM
vanadate, and 1mMPMSF). Total proteins (cleared supernatant)
were separated by centrifugation from the cell lysate. Protein
concentrations were measured using Bio-Rad protein assay
kit (Bio-Rad Laboratories) according to the manufacturer’s
guidelines. Total protein contents were separated by 12.5%
SDS-PAGE and blotted onto PVDF membrane (0.45µm pore
size, Immobilon, Millipore, MA, USA) using Trans-Blot SD
cell system (Bio-rad, Munich, Germany) for 30min at 15V
in a blotting buffer [192mmol/L glycine, 20% methanol, and
25mmol/L Tris (pH 8.3)]. To prevent nonspecific binding sites,
each membrane was blocked with 5% milk (w/v) in TBS-T
buffer [50mmol/L Tris–HCl (pH 7.5), 200mmol/L NaCl, 0.05%
Tween 20] for 1 h at room temperature. Blocked membranes
were washed twice in TBS-T for 5min, then incubated with
TABLE 1 | Promotor assay and mRNA expression primer list.
Name Chromosomal
location
Direction Promoter assay primers Expression primers
Sequences Product size (bps) Sequences Product size (bps)
p38MAPK 6 Forward TTTGACTCTTTCCCCGACAC 187 CCAGCTTCAGCAGATTATGC 246
Reverse AACTGGAGACCAAAGGCAGA TGGTACTGAGCAAAGTAGGCA
ATF-2 2 Forward CCTCAGCATACTGGTGCATT 159 GGCTTCTCCAGCTCACACA 326
Reverse TGGATGTGCTGACCGAACTA TGTTTCAGCTGTGCCACTTC
MLCK 3 Forward TCTGCTGCAGTTCAGAGCAA 150 GATGATGCTCCAGCCAGT 177
Reverse AGGAGGAATGGTCAACAGCA GTCCTCAGGGAACTGGATGA
MLC-2 12 Forward TCCACCTCCATCTTCTTTGC 168 AGAGACACCTTTGCTGCCCTT 188
Reverse GCCTTTGCCTTCCTTACACA CCTTTGCCTTCAGGGTCAAAC
Occludin 5 Forward TGGATGGCAACTAACACCTACA 142 TGGGACAGAGGCTATGGAAC 287
Reverse AACGAAAGACTCCTGGGAAAAT ATGCCCAGGATAGCACTCAC
ZO-1 15 Forward GCACATCAGCACGATTTCTG 166 TGAGGCAGCTCACATAATGC 224
Reverse AAACAGTGGGCAAACAGACC GGTCTCTGCTGGCTTGTTTC
GAPDH 12 Forward TGAGCAGTCCGGTGTCACTA 152 ACCCAGAAGACTGTGGATGG 201
Reverse ACGACTGAGATGGGGAATTG TTCTAGACGGCAGGTCAGGT
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following antibodies: 1:10,000 dilution of mouse monoclonal
anti-MLCK antibody (Sigma, Mannheim, Germany), 1:500
dilution of a mouse monoclonal anti-MLC-2 antibody (Sigma,
Mannheim, Germany), 1:1000 rabbit anti-phospho MLC-2
antibody (Cell Signaling, Beverly, USA), 1µg/mL rabbit anti-
ZO-1, 0.5µg/mL mouse anti-occludin (Zymed, CA, USA),
1:500 dilution of rabbit anti-H3K9ac (abcam), 1:250 dilution of
H4K8ac (diagenode), or 1:5000 anti-β actin (Sigma, Mannheim,
Germany) in 5% BSA in TBS-T for overnight at 4◦C. Following
overnight incubation with primary antibodies, membranes
were washed with TBS-T buffer and again incubated with
appropriate HRP-conjugated secondary antibodies (Bio-Rad,
Munich, Germany), then washed with PBS and arranged for
enhanced chemiluminescence detection (GE, Buckinghamshire,
UK) according to the manufacturer’s recommendation. The
chemiluminescence signal was captured by hyperfilm-ECL (GE,
Buckinghamshire, UK) and visualized using Konica SRX-101A
(Konica Minolta). The densities of the specified protein bands
between MPA-treated, SB plus MPA and control samples were
quantified using ImageJ software (v 1.48, NIH, USA).
Chromatin Immunoprecipitation (ChIP)
Caco-2 cells were cultured and treated as earlier described in “cell
culture.” For ChIP analysis, cells were fixed with formaldehyde at
a final concentration of 1.0% for 30min at room temperature to
cross-link DNA binding proteins and DNA (Boyd et al., 2009).
Cells were harvested with ice cold PBS and counted by Advia
120 (Siemens) and equal number of cells were lysed according
to the manufacturer’s instructions (Red ChIP Kit™, Diagenode).
Cross-linked chromatin was sheared into fragments of 100–1000
bps using Branson Sonifier 250 for 3min using cycles of 30 s
sonication and 1min on ice. One-tenth of the sample was set
aside as an input control, and the rest was pre-cleared with
protein A magnetic beads for 30min at 4◦C with agitation. Pre-
cleaned chromatin was then precipitated with active histone
mark antibody (H3K4me3, Abcam, ab8580), as well as with
repressive histone mark antibody (H3K27me3, Millipore, 07-
449), and normal IgG (One Day ChIP Kit™, Diagenode) from
both treated and untreated cells. The Chromatin-antibodies-
magnetic beads complexes were washed with 1X ChIP washing
buffer (One Day ChIP Kit™, Diagenode). Proteinase K was
used to degrade the DNA associated proteins and DNA was
isolated by DNA slurry (One Day ChIP Kit™, Diagenode) and
quantified by NanoDrop (NanoDrop 2000C, peqlab, Thermo
Scientific). ChIP-precipitated genomic DNA was amplified using
real time PCR (Roche, Manheim, Germany) in 20µL SYBR
green based reaction (For promoter based primers see details
in Table 1). PCR amplification was done under the following
conditions; [(denaturation: 95◦C for 2min, one cycle); (40 cycles,
denaturation: 95◦C for 30 s, (annealing: p38MAPK (60◦C), ATF-
2 (55◦C), MLCK (62◦C), MLC-2 (62◦C), occludin (54◦C), ZO-1
(55◦C), and GAPDH (59◦C) for 30 s), extension (72◦C) for 30 s)].
Data Analysis
Ct-values from real time PCR were analyzed by “input percent
method” (Lin et al., 2012). Briefly, raw Ct-value of the diluted
input (1%) was adjusted to 100% by subtracting the dilution
factor of 100 or 6.644 cycles (i.e., log2 of 100). Sample raw Ct-
values (1Ct) were normalized by subtracting adjusted Input (Ct
Input –6.644) Ct-value. And finally the “Input percent” value for
each sample was calculated using the following formula. Input %
= 100 ∗ 2ˆ(adjusted input – Ct IP). The “Input percent” value
represents the enrichment of H3K4me3 and/or H3K27me3 at
the promoter region of genes studied. Dissociation curve analysis
was performed to confirm the specificity of each PCR product.
GAPDH was used as an internal control gene.
Statistics
Statistical program GraphPad (GraphPad, San Diego, CA)
was used to perform statistical analysis. Data was analyzed
by analysis of variance (ANOVA) and comparisons between
control and MPA treatment were made using the Bonferroni
posttest. Alternatively, statistical significance between control
and treatment group were calculated using student’s t-test.
Results were expressed as mean ± standard error of the mean
(SEM). Probability of 0.05 or less was deemed statistically
significant (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
RESULTS
MPA Increases Global Histone (H3K9 and
H4K8) Acetylation in Caco-2 Cells
Acetylation of histone proteins plays an important role in the
unfolding of chromatin and initiation of transcription. Recently
it was reported that MPA treatment increases the histone H3/H4
global acetylation levels in CD4+ T cells from systemic lupus
erythematosus patients (Yang et al., 2015). In order to study
whether MPA treatment leads to similar epigenetic changes
also in epithelial monolayer, Caco-2 cells monolayers were
treated with MPA for various time points and analyzed for
global histone acetylation levels using dot- and Western -blot
analysis. The dot blot results show that MPA treatment increases
global acetylation of H3K9 and H4K8 in Caco-2 cells after 72 h
(Figure 1A). Western blot analysis further confirmed that MPA
significantly increases the acetylation of H3K9 and H4K8 after
72 h (Figures 1B–D). These results indicate that MPA treatment
significantly alters the epigenetic status of Caco-2 cells.
MPA Treatment Activates MLCK and
MLC-2 While Inactivates Occludin at
Epigenetic Level in Caco-2 Cells
We and other investigators have reported the involvement
of MLCK pathway in the regulation of TJs barrier function
(Cunningham and Turner, 2012; Qasim et al., 2014). In light
of the global increase in histone acetylation levels after MPA
treatment, we assessed the epigenetic status at the promoter
region of MLCK, MLC-2, occludin, and ZO-1 genes, by ChIP
assay in MPA treated or untreated Caco-2 monolayer cells. Our
ChIP data showed that the transcription permissive histone
modification mark (H3K4me3) was increased significantly at
the promoter region of MLCK and MLC-2 genes, respectively
(Figures 2A,B). Concomitantly, transcription repressive mark
(H3K27me3) was decreased significantly at the promoter region
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FIGURE 1 | MPA treatment increases global histone acetylation in
Caco-2 cells. (A) Dot-blot analysis; Caco-2 cells were cultured in six-well
plates and post confluence monolayers were treated either with 10µM MPA or
DMSO for indicated time points. Total proteins were extracted and a volume of
2µl from each time point was spotted on nitrocellulose membrane, dried and
then probed with anti-H3K9ac and anti-H4K8ac antibodies. (B) Western blot
analysis; Total cell proteins were resolved on 12.5% SDS-PAGE gels and,
immunoblotted using anti-H3K9ac and anti-H4K8ac specific antibodies.
β-actin was used as a loading control. (C,D) Bar graphs representing the
densitometric analysis of three independent experiments from Western blot (B)
using the Lab image software. Differences between two groups were analyzed
by the two-tailed Student’s t-test and of more than two groups by One-way
ANOVA with Bonferroni posttest (n = 3) and the values were expressed as
means ± SEM. Asterisk indicates the significance (***P < 0.001) when
compared to control cells. ns, non-significant.
ofMLCK andMLC-2 genes, respectively, as compared to controls
(Figures 2A,B). While promoter of occludin lost H3K4me3 mark
and gained H3K27me3 mark in the MPA treated Caco-2 cells as
compared to control cells, indicating the transcriptional silencing
of occludin after MPA treatment (Figure 2C). However, the
promoter region of ZO-1 showed no significant changes in
H3K4me3 and H3K27me3 levels between MPA-treated cells and
control (Figure 2D).
To confirm the influence of MPA on the epigenetic
activation of MLCK and MLC-2 genes, transcriptional and
translational expression was analyzed using quantitative PCR
and immunoblotting, respectively. In line with the earlier reports
(Qasim et al., 2011, 2014), MPA treatment significantly increased
the expression of MLCK and MLC-2 both at transcriptional
and protein level (Figures 2E–G). Further we analyzed the
expression of occludin to confirm the epigenetic data at mRNA
and protein level and found significant decrease at protein
and mRNA expression (Figures 2E–G). In contrast, we did not
observe any significant difference in ZO-1 RNA or proteins
expression in MPA-treated Caco-2 cells as compared to control
cells (Figures 2E–G). Collectively, the gene expression data
correlate well with the gene-specific epigenetic changes induced
by MPA treatment in Caco-2 monolayer cells.
MPA Treatment Activates p38MAPK and
ATF-2 at Epigenetic Level in Caco-2 Cells
Recently it was reported that p38MAPK increases TJs
permeability in IL-1β treated Caco-2 through activation of
MLCK pathway (Al-Sadi et al., 2013). In this study we aimed to
extend our previous knowledge and explored whether p38MAPK
acts upstream of MLCK/MLC-2 pathway in MPA-treated Caco-2
cells. Toward this end, firstly, we assessed the epigenetic status of
p38MAPK and ATF-2 genes at their promoter regions by ChIP
assay in MPA treated or untreated Caco-2 monolayer cells. Our
ChIP results showed that the activation histone modification
mark (H3K4me3) was increased significantly at the promoter
region of p38MAPK and ATF-2 genes, respectively, in MPA
treated cells (Figures 3A,B). Concomitantly, repression mark
(H3K27me3) was decreased significantly at the promoter region
of p38MAPK and ATF-2 genes, respectively, as compared to
controls (Figures 3A,B). The transcriptionally active epigenetic
state of p38MAPK and ATF-2 was confirmed by the mRNA
expression analysis that showed significant increase in p38MAPK
and ATF-2 expression after MPA (Figure 3C).
Inhibition of p38MAPK via SB Counteracts
the Altered Expression of MLCK, MLC-2,
and Occludin Genes in MPA-treated
Caco-2 Cells
In order to test whether MPA indeed regulates p38MAPK-
dependent expression of MLCK pathway and thereby the TJs
defects, we performed the p38MAPK inhibition and studied
its effect at the functional level. The chemical inhibitor
SB203580 (SB), a representative of pyridinlimidazole, is a specific
inhibitor of p38MAPK and is widely used in inhibitory studies
to attenuate the activity of p38MAPK and its downstream
signaling activities in various physiological processes (Kumar
et al., 1999). Our results showed that p38MAPK inhibition in
MPA treated Caco-2 cells prevented any significant change in
expression of MLCK, MLC-2, phosphorylated MLC-2 (pMLC-
2), and Occludin protein as compared to DMSO only treated
cells (Figures 3D–G). While the expression of ZO1 was
found unaltered by MPA or MPA+SB treated Caco-2 cells
(Figure 3H).
p38MPAK Inhibition Partially Reverses
MPA-induced TJs Dysfunction
The maintenance of normal protein levels of MLCK, MLC2, and
occludin after p38MAPK inhibition prompted us to study the
functional properties of Caco-2 monolayer in the presence of
SB. The intactness of Caco-2 cells differentiated into polarized
confluence monolayer can be measured quantitatively as TEER-
value and the sum of the resistance indicates the integrity
of the monolayer barrier maintained by TJs in the apical
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FIGURE 2 | MPA causes epigenetic alteration of MLCK/MLC-2 pathway and tight junction genes (occludin). (A–D) Caco-2 cells were grown for 13 days
post-confluence to form differentiated monolayers and then treated for 72 h with MPA or DMSO. ChIP was performed using anti-H3K4me3 (activation mark) or
anti-H3K27me3 (repression mark), followed by real time PCR using promoter-specific primers of the target genes (MLCK, MLC-2, Occludin, and ZO-1). Levels of
H3K4me3 or H3K27me3 was measured as %age input in the MPA treated cells as compared to the untreated cells. (E,F) Western blot analyses of MLCK, MLC-2,
occludin, and ZO-1 after MPA treatment. Whole cell protein lysates were resolved on SDS-PAGE gels and immunoblotted using of anti-MLCK, anti-MLC-2,
anti-occludin, and anti-ZO-1 specific antibodies. β-actin was used as a loading control for an equal amount of protein. Densitometric analysis was done using the Lab
image software on three independent experiments. Differences between two groups were analyzed by the two-tailed Student’s t-test and of more than two groups by
One-way ANOVA with Bonferroni posttest. (G) DMSO treated Caco-2 monolayer cells. The values were expressed as means ± SEM. Asterisk indicates the
significance (**P < 0.01, ***P < 0.001) when compared to control cells. (n = 3). ns, non-significant.
surface of the cells. Any damage to the intactness of monolayer
results in reduced TEER-value. In accordance with the literature,
exposure of Caco-2 monolayer to MPA significantly decreased
TEER at 24 h after treatment, and the TEER was significantly
further decreased by 72 h as compared to the control cells
(Figure 3I). Similarly, FD4 permeability analysis (traditionally
used to measure the movement of small molecules across the
intestinal epithelium in vivo) following 72 h MPA treatment
showed a time-dependent increase across (from the apical
to the basolateral side) the Caco-2 monolayer, as expected
(Figure 3J).
Interestingly, when MPA-treated Caco-2 cells monolayers
were co-incubated with the inhibitor for p38MAPK, very
significant preservation of TEER (∼50%) was observed as
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FIGURE 3 | p38MAPK regulates MLCK/MLC-2 pathway and its inhibition partially prevents MPA-induced TJs dysfunction. (A,B) Epigenetic status at the
promoter regions of p38MAPK and ATF-2 genes MPA or DMSO treated Caco-2 monolayer cells. ChIP was performed with antibodies specific to the activation mark
(H3K4me3) or repression mark (H3K27me3), followed by real time PCR analysis. Relative intensity of activation mark (H3K4me3) or repression mark (H3K27me3) were
measured as %age input. (C) Bar graph showing the p38MAPK and ATF-2 mRNA expression. (D–H) Western blots and the corresponding densitometric data
showing the effect of SB on the expression of MLCK/MLC-2 pathway and tight junction proteins (occludin and ZO-1). (I,J) Line graphs showing the transeplithelial
electrical resistance (TEER) (I) and paracellular flux (FITC-dextran) (J) assay results obtained either in presence or absence of p38MAPK inhibitor. Error bar indicate
means ± SEM. Asterisk indicates the significance (*P < 0.05, **P < 0.01, ***P < 0.001) when compared to control cells. (n = 3). ns, non-significant.
compared to only MPA-treated Caco-2 cells (Figures 3I,J).
Similarly, 50% reduction in the FD4 leak on the basolateral
side of the Caco-2 cell monolayer was measured as compared
to only MPA-treated monolayer (Figure 3J). Collectively,
these results confirm that the Caco-2 monolayer paracellular
permeability is significantly increased after MPA exposure and
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that can be antagonized by blocking the activity of p38MAPK
pathway.
Inhibition of p38MAPK Through SB
Demolishes Increased Promoter Activity of
Downstream Targets of p38MPAK in
MPA-Treated Caco-2 Cells
Next, we analyzed whether the protein expression changes seen
after the inhibition of p38MAPK are due to the epigenetic
remodeling at the promoter regions of these genes or are due
to protein stability. In accordance with the expression data
of downstream targets of p38MAPK, the epigenetic signature
at the promoter regions of MLCK, MLC-2, and Occludin, but
not ZO1, was restored to the epigenetic status seen in control
cells (Figures 4A–D) by SB use. Similarly, by use of SB, the
promoter region of ATF2, but not p38MAPK, showed the normal
chromatin signature seen in control cells (Figures 4E,F). These
results were further confirmed by mRNA expression analysis,
which showed that pretreatment with SB restored the MPA
induced gene expression changes in Caco-2 cells while it had
no significant inhibitory effects on mRNA expression of the
p38MAPK gene (Figures 5A–C).
DISCUSSION
Regulation of TJs barrier function, that controls paracellular
movement, is a vital and complex process involving complicated
intracellular signaling pathways and organization of TJs
proteins leading to influence the passage of ions and solutes
FIGURE 4 | Inhibition of p38MAPK counteracts MPA-mediated epigenetic remodeling. Effect of SB203580 on promoter activity of p38MAPK mediated
MLCK/MLC-2 pathways and TJs genes in MPA-treated Caco-2 Cells. (A–F) Bar graphs showing the epigenetic status at the promoter regions of MLCK, MLC-2,
occludin, ZO-1, p38MAPK, and ATF-2 genes in either presence or absence of p38MAPK inhibitor. The ChIP-qPCR data was expressed as means ± SEM. Asterisk
indicates the significance (**P < 0.01, ***P < 0.001) when compared to control cells. Differences between two groups were analyzed by the two-tailed Student’s t-test
and of more than two groups by One-way ANOVA with Bonferroni posttest. ns, non-significant.
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via paracellular movement across the epithelial monolayer
(Anderson and Van Itallie, 1995; González-Mariscal et al., 2008).
On the basis of initial morphological descriptions, TJs were
characterized as a defined structure, both physiologically and
morphologically (Farquhar and Palade, 1963). However, later
it was accepted that TJs are a dynamically regulated structure
(Pappenheimer, 1987; Taylor et al., 1998). The barrier function
of epithelial monolayer depends upon the continuity of the
monolayer and intact TJs (Anderson and Van Itallie, 1995, 2009;
Hering et al., 2012). Intestinal barrier dysfunction through TJs
disruption is characterized by increased paracellular permeability
along with altered expression and organization of TJs proteins
(Clayburgh et al., 2004; Prasad et al., 2005). Subsequently, other
investigators and we have reported MLCK activation, which
directly leads to the phosphorylation of MLC-2, as a common
final pathway of acute TJs regulation in response to a broad
range of physiological or pathophysiological stimuli (Turner,
2006, 2009; Qasim et al., 2014). Phosphorylation of MLC-2
through activated MLCK alone is sufficient to increase TJs
permeability, which is associated with redistribution of ZO-1
and occludin (Al-Sadi et al., 2013). Previously, we have shown
that therapeutic dose of MPA caused the increased permeability
of Caco-2 monolayer, and this outcome is accompanied by
increased activity ofMLCK/MLC-2 pathway (Qasim et al., 2014).
In this context, it is interesting to note that proinflammatory
cytokine (IL-1β) induced increase in intestinal TJs permeability
in both in vitro and in vivo models is mediated through
p38MAPK/ATF-2-dependent regulation of MLCK activity
(Al-Sadi et al., 2013). In this study, we wanted to extend our
previous knowledge of TJs regulation via MLCK pathway in
response to MPA. Our data highlight that MPA alters the
chromatin structure leading to deregulated expression of genes
implicated in TJs function. We identified that p38MAPK and
ATF-2 pathway is activated in MPA treated Caco2 monolayer
and this pathway was found regulate the MLCK/MLC-2
activity. Interestingly, pharmacological inhibition of p38MAPK
counteracted the altered gene expression of MLCK/MLC-2 and
thereby maintained the normal function of TJs. Chromatin
structure is modulated by the well documented posttranslational
modification of histone proteins (Strahl and Allis, 2000). More
than 100 different types of posttranslational modifications
that include; acetylation, methylation, phosphorylation, and
ubiquitination can occur to the amino-terminal tails of histones,
which form the nucleosomes of chromatin (Bernstein et al.,
2007; Kouzarides, 2007). Majority of these modifications remain
poorly understood, however, considerable progress has been
made in the understanding of lysine acetylation and methylation
of histones in recent years. Lysine acetylation is mostly
correlated with nucleosome assembly, chromatin accessibility
and transcriptional activity, whereas lysine methylation effects
depend upon the modified residue (Bernstein et al., 2007).
Acetylated H3K9 (Nishida et al., 2006) and H4K8 are well-
known epigenetic markers that are present at the promoter
regions of transcriptionally active genes (Gupta et al., 2013).
Their levels are strongly correlated with the gene expression
therefore referred as “transcription-linked” histone marks
(Suzuki et al., 2008; Gupta et al., 2013). Our global histone
acetylation analysis showed significant increase in acetylation
FIGURE 5 | p38MAPK inhibition preserves normal MLCK/MLC-2 gene expression in Caco2 cells treated with MPA. Bar graphs showing the mRNA
expression levels of MLCK and MLC-2 (A), occludin and ZO-1 (B), and p38MAPK and ATF-2 (C) in either presence or absence of p38MAPK inhibitor. Values are
expressed as means ± SEM. Asterisk indicates the significance (**P < 0.01, ***P < 0.001) when compared to control cells. Differences between two groups were
analyzed by the two-tailed Student’s t-test and of more than two groups by One-way ANOVA with Bonferroni posttest. ns, non-significant.
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at H3K9 and H4K8. This global chromatin change observed
after MPA treatment is in agreement with a recent report
showing that MPA treatment induces global H3/H4 acetylation
in CD4(+)T cells to exert therapeutic effects in systemic lupus
erythematosus patients (Yang et al., 2015). In this context,
it is interesting to note that hydroxamic acid derivatives of
MPA were shown to function as histone deacetylase (HDAC)
inhibitors (Batovska et al., 2008). Owing to these evidences, it
is interesting to speculate that MPA might exert its therapeutic
effect on immune cells not only by blocking IMPDH, but also
by acting as epigenetic modifier. And this epigenetic effect
might also occur in non-immune cells such as epithelial cells
leading to gene expression changes and unwanted phenotypic
changes.
Trimethylation of H3K4 is found at more than 90% of the
RNA polymerase II binding regions (Barski et al., 2007) at
the promoter region of protein coding genes and is linked to
gene activation, whereas trimethylation of H3K27 is linked to
repression of the gene (Barski et al., 2007; Guenther et al.,
2007). Our ChIP-qPCR data showed significant enrichment of
H3K4me3 at the promoter regions of MLCK and MLC-2 genes,
enrichment of H3K27me3 at the promoter region of Occludin,
while no change in H3K4me3 and H3K27me3 levels at ZO-1
promoter region after MPA treatment. The gene expression
analyses at transcriptional and translational level further
strengthened the epigenetic activation of MLCK and MLC-2
genes and repression of occludin gene. Interestingly, Inhibition
of p38MAPK with SB prevented the MPA mediated epigenetic
changes as well as the gene expression pattern. Presence of SB
together with MPA, significantly but not completely reduced the
MPA induced TJs permeability, suggesting role for additional
signaling pathways/proteins in TJs deregulation in MPA-treated
Caco-2 cells. In view of current data, it would be interesting
to check whether p38MAPK conditional knockout mice could
alleviate or completely block the MPA-mediated TJs dysfunction.
Therefore, a more detailed analysis of TJs proteins regulation as
well as their regulating pathway(s) is necessary to understand
the mechanism of leak flux diarrhea in in vitro model that is
comparable to in vivomodel of MPA therapy.
CONCLUSIONS
In summary, this study provides new insights and an essential
understanding into the mechanisms of MPA-mediated decrease
in intestinal epithelial barrier function. Our data pointed out
epigenetic activation of p38MAPK, ATF-2, MLCK, and MLC-
2 genes whereas repression of occludin gene at promoter level
(Figure 6). To the best of our knowledge, this is the first in vitro
FIGURE 6 | Proposed mechanism of MPA-induced TJs assembly deregulation in Caco-2 cells monolayer. Proinflammatory cytokines (as observed in IBD)
directly or through p38MAPK activate the MLCK pathway which leads to the altered TJs proteins contents and composition in TJs assembly, resulting in
compromised epithelial barrier function. This compromised barrier function contributes to leaky style diarrhea in IBD patients. Identification of altered chromatin
structure at p38MAPK, ATF-2, MLCK, and MLC-2 promoter regions after MPA treatment allow us to assume that MPA either directly or through unknown mediators
activates the p38MAPK cascade. Activation of the p38MAPK-dependent MLCK/MLC-2 pathway consequently reorganizes F-actin base cytoskeleton, redistribute
ZO-1 and occludin proteins of TJs assembly, resulting in increased permeability of Caco-2 monolayer.
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experimental study that provides direct evidence to indicate
the role of chromatin remodeling in the p38MAPK-dependent
MLCK pathway activation in response to MPA exposure.
From these results, it can be hypothesized that comparable
barrier function modulations may occur in the patients under
MPA therapy leading to GI tract complication in some organ
transplanted patients.
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